Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C19H16N2O6 and a molecular weight of 368.34 g/mol[6][7][9]. It is primarily used as an experimental or research tool and does not have any approved medical indications. The compound has been identified as a ligand for heat shock protein HSP 90-alpha (HSP90AA1), with reported binding affinity (Kd) of approximately 680 nM[6]. HSP90 is a molecular chaperone involved in the folding and stabilization of many proteins required for tumor growth; thus, inhibitors of HSP90 are being explored as potential antineoplastic agents. However, there is no evidence that this molecule has advanced beyond preclinical or early experimental stages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(1,3-benzodioxol-5-yl)-5-(5-ethyl-2,4-dihydroxyphenyl)-2h-pyrazole-3-carboxylic acid.